Smith & Nephew H1 FY26 trading profit rises 8.1% to $566 million

• Smith & Nephew H1 trading profit rose 8.1% to $566 million.
• Adjusted EPS climbed 11.0% to 47.7.
• Underlying revenue growth was 1.6% in Q2, with softness in U.S. Orthopaedics and Advanced Wound Bioactives.
• Cut full-year revenue outlook, now expecting about 4.0% growth; maintained guidance for trading profit, free cash flow, ROIC.
• Added $50 million of 2026 savings to offset lower revenue growth; H1 trading cash conversion fell to 77%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Smith & Nephew plc published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.